
    
      This study is being carried out in two parts,part 1 and part 2. Part 1: This is the
      dose-escalation part. The primary purpose of the part 1 portion is to determine the dose
      limiting toxicity (DLT) and maximum tolerated dose (MTD), and recommend the appropriate doses
      of CT053PTSA for further study Part 2: This is the expansion part.The part 2 portion of this
      study will continue to evaluate the safety and efficacy of CT053PTSA at the appropriate dose
      recommended in Part 1,in patients with advanced and metastatic RCC
    
  